Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Sara Galimberti, Stefano Luminari, Elena Ciabatti, +26

Clinical Cancer Research

Hematological MalignancyPcr StatusMrd NegativityLymphoid NeoplasiaMedicine +11

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

Antonello Di Paolo, Marialuisa Polillo, Matteo Capecchi, +13

The Pharmacogenomics Journal

Hematological MalignancyChronic Myeloid LeukemiaG PolymorphismMedicineGenetic Epidemiology +6

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

Sara Galimberti, Mario Petrini, Claudia Baratè, +12

Frontiers in Oncology

The CoV-2 outbreak: how hematologists could help to fight Covid-19

Sara Galimberti, Chiara Baldini, Claudia Baratè, +11

Pharmacological Research

Virus EpidemiologyCov-2 OutbreakCovid-19 PandemicVirologyCovid-19 Epidemiology +4

Real‐Time <scp>PCR</scp> and Droplet Digital <scp>PCR</scp>: two techniques for detection of the <i><scp>JAK</scp>2</i>^<i>V617F</i> mutation in Philadelphia‐negative chronic myeloproliferative neoplasms

Giulia Fontanelli, Claudia Baratè, Elena Ciabatti, +10

International Journal of Laboratory Hematology

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

Susanna Grassi, Francesca Guerrini, Elena Ciabatti, +13

Cancers

EngineeringMixed-phenotype Acute LeukemiaGeneticsSensitive ToolPathology +17

The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia

Francesca Guerrini, Matteo Paolicchi, Francesco Ghio, +13

Frontiers in Pharmacology

The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia

Sara Galimberti, Susanna Grassi, Claudia Baratè, +22

Frontiers in Oncology

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia

Susanna Grassi, Sara Palumbo, Veronica Mariotti, +19

Frontiers in Oncology

Minimal residual disease (MRD) in non‐Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network

Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, +19

Hematological Oncology

ImmunodeficienciesImmunologyDiagnosisPathologyMyeloid Neoplasia +25